GC Biopharma Corp (006280) Fair Value & Analysis

Healthcare · KR · Market cap 1.4T KRW

Below-average quality, and screening another 76% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (57,527 KRW). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (31,777 KRW to 57,527 KRW) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 91,716 KRW – 385,111 KRW · fair‑value band 31,777 KRW – 57,527 KRW · the 129,900 KRW price screens above the 31,777 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

GC Biopharma Corp (006280) currently trades at 129,900 KRW, while our model-based Fair Value estimate is 31,777 KRW, implying the stock looks roughly 75.5% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, GC Biopharma Corp generated revenue of 2.0T KRW at a net margin of -0.7%. Revenue grew 13.5% year over year. It earns a return on equity of -2.3%. Net debt stands at 813B KRW. Fundamentals as of Jul 22, 2026

Our scenario range runs from 31,777 KRW (bear case) to 57,527 KRW (bull case); at 129,900 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -76%, 006280 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (85,114 KRW) versus Earnings-Based (17,755 KRW). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally.

Full company description

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; and Varicella Vaccin. It has a research and development agreement with Novelty Nobility to develop antibody-based therapeutics for geographic atrophy. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

GC Biopharma Corp reported revenue of 2.0T KRW in FY2025 versus 1.5T KRW in FY2021, a compound +6.7%/yr. Reported net income was −4.7B KRW in FY2025.

006280 screens 76% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.